These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 20435228)

  • 1. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.
    ; Thompson A; Gao P; Orfei L; Watson S; Di Angelantonio E; Kaptoge S; Ballantyne C; Cannon CP; Criqui M; Cushman M; Hofman A; Packard C; Thompson SG; Collins R; Danesh J
    Lancet; 2010 May; 375(9725):1536-44. PubMed ID: 20435228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
    ; Kaptoge S; Di Angelantonio E; Lowe G; Pepys MB; Thompson SG; Collins R; Danesh J
    Lancet; 2010 Jan; 375(9709):132-40. PubMed ID: 20031199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up.
    Rallidis LS; Tellis CC; Lekakis J; Rizos I; Varounis C; Charalampopoulos A; Zolindaki M; Dagres N; Anastasiou-Nana M; Tselepis AD
    J Am Coll Cardiol; 2012 Nov; 60(20):2053-60. PubMed ID: 23083783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study.
    Suzuki T; Solomon C; Jenny NS; Tracy R; Nelson JJ; Psaty BM; Furberg C; Cushman M
    Circ Heart Fail; 2009 Sep; 2(5):429-36. PubMed ID: 19808373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Caslake MJ; Packard CJ; Robertson M; Cooney J; Nelson JJ; Ford I; Gaw A; Jukema JW; Macfarlane PW; Stott DJ; Shepherd J;
    Atherosclerosis; 2010 May; 210(1):28-34. PubMed ID: 20005516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of lipoprotein-associated phospholipase A
    Han L; Zhong C; Bu X; Xu T; Wang A; Peng Y; Xu T; Wang J; Peng H; Li Q; Ju Z; Geng D; Zhang Y; He J;
    Atherosclerosis; 2017 Nov; 266():1-7. PubMed ID: 28934604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual activity of serum lipoprotein-associated phospholipase A(2) yielding positive and inverse associations with cardiometabolic risk.
    Onat A; Hergenç G; Can G; Uğur M; Nartop F
    Clin Chem Lab Med; 2011 Aug; 49(8):1349-1357. PubMed ID: 21756164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein-associated phospholipase A₂ activity and mass in relation to vascular disease and nonvascular mortality.
    Heart Protection Study Collaborative Group
    J Intern Med; 2010 Oct; 268(4):348-58. PubMed ID: 21050287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study.
    Kim JY; Hyun YJ; Jang Y; Lee BK; Chae JS; Kim SE; Yeo HY; Jeong TS; Jeon DW; Lee JH
    Am J Clin Nutr; 2008 Sep; 88(3):630-7. PubMed ID: 18779277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden.
    Persson M; Berglund G; Nelson JJ; Hedblad B
    Atherosclerosis; 2008 Sep; 200(1):191-8. PubMed ID: 18201705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians.
    Anuurad E; Ozturk Z; Enkhmaa B; Pearson TA; Berglund L
    J Clin Endocrinol Metab; 2010 May; 95(5):2376-83. PubMed ID: 20194707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
    J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.
    ; Erqou S; Kaptoge S; Perry PL; Di Angelantonio E; Thompson A; White IR; Marcovina SM; Collins R; Thompson SG; Danesh J
    JAMA; 2009 Jul; 302(4):412-23. PubMed ID: 19622820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.
    Ridker PM; MacFadyen JG; Wolfert RL; Koenig W
    Clin Chem; 2012 May; 58(5):877-86. PubMed ID: 22419750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study.
    Jenny NS; Solomon C; Cushman M; Tracy RP; Nelson JJ; Psaty BM; Furberg CD
    Atherosclerosis; 2010 Apr; 209(2):528-32. PubMed ID: 19804884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature.
    Gregson J; Stirnadel-Farrant HA; Doobaree IU; Koro C
    Atherosclerosis; 2012 Nov; 225(1):11-21. PubMed ID: 22784637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of lipoprotein-associated phospholipase A₂ with characteristics of vulnerable coronary atherosclerotic plaques.
    Liu YS; Hu XB; Li HZ; Jiang WD; Wang X; Lin H; Qin AQ; Wang YM; Zhao T; Dong ZQ; Zhang M; Lu QH
    Yonsei Med J; 2011 Nov; 52(6):914-22. PubMed ID: 22028154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis.
    Hu G; Liu D; Tong H; Huang W; Hu Y; Huang Y
    Biomed Res Int; 2019; 2019():8642784. PubMed ID: 31236414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein-associated phospholipase A(2) activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients.
    Delgado P; Chacón P; Penalba A; Pelegri D; García-Berrocoso T; Giralt D; Santamarina E; Ribó M; Maisterra O; Alvarez-Sabín J; Rosell A; Montaner J
    Cerebrovasc Dis; 2012; 33(2):150-8. PubMed ID: 22178747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.